DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Liabilities | ₹14,857 Cr | ₹14,619 Cr | ₹11,387 Cr | ₹9,425 Cr | ₹8,795 Cr |
What is the latest Total Liabilities ratio of DIVIS LABORATORIES ?
Year | Total Liabilities |
---|---|
Mar2023 | ₹14,857 Cr |
Mar2022 | ₹14,619 Cr |
Mar2021 | ₹11,387 Cr |
Mar2020 | ₹9,425 Cr |
Mar2019 | ₹8,795 Cr |
How is Total Liabilities of DIVIS LABORATORIES Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹14,857 Cr | 1.62 | |
Mar2022 | ₹14,619 Cr | 28.39 | |
Mar2021 | ₹11,387 Cr | 20.82 | |
Mar2020 | ₹9,425 Cr | 7.16 | |
Mar2019 | ₹8,795 Cr | - |
Compare Total Liabilities of peers of DIVIS LABORATORIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
DIVIS LABORATORIES | ₹114,429.2 Cr | 1.3% | 8.7% | 26.8% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹350,339.0 Cr | -0.5% | -3.8% | 50.8% | Stock Analytics | |
CIPLA | ₹116,930.0 Cr | -2% | 2% | 53.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,694.0 Cr | -5.5% | 1.3% | 99.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹96,546.9 Cr | -1.7% | -8% | 28.9% | Stock Analytics | |
MANKIND PHARMA | ₹85,978.3 Cr | 1.5% | -8.1% | 53.1% | Stock Analytics |
DIVIS LABORATORIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DIVIS LABORATORIES | 1.3% |
8.7% |
26.8% |
SENSEX | -1.9% |
-0.7% |
18.3% |
You may also like the below Video Courses